Marc Beer And Renovia Are Changing Women’s Health

There are a lot of different health issues that affect women more than men and in many cases, these health problems do not get as much attention as others that affect both sexes. Marc Beer, the CEO of Renovia, is dedicated to making sure that certain health issues that women faced are addressed, researched, and treated properly through his newly founded company. In fact, Renovia has raised millions of dollars in order to do just that. In his second round of fundraising, Renovia was able to raise $32 million and venture debt of $10 million to help the company achieve their goals.

Renovia is a medical technology company based out of the city of Boston. Their current focus is the development and distribution of products that are meant to diagnose, study, and treat different types of pelvic floor disorders. Pelvic floor disorders can happen in women during any time of their lives. While these types of disorders that Marc Beer hopes to improve generally happen among the older population, they are common after childbirth and other situations as well. One of the most uncomfortable symptoms that go with the disorders is urinary incontinence. While the pain is also uncomfortable, it generally isn’t as inconvenient for patients with the disorder as the incontinence.

Renovia has already had one of their products used for pelvic floor disorders approved for sale in the United States by the Food and Drug Administration. Marc Beer’s company received the approval for this product back in April of this year and are looking forward to other products in their pipeline getting approved as well. The product that was approved is a device known as Leva. Renovia is currently working on making improvements to this device so it can offer even more benefits. Along with the new generation of Leva device, they have 3 other products involved with diagnosis and therapy. The funding that was raised will go towards the testing and development of all of these products.

Marc Beer has been in the biotech industry for longer than 2 decades and has had extensive experience in the worlds of commercialization and development in the healthcare industry. The current chief executive and chairman of Renovia is also a chairman on the boards of Good Start Genetics and Minerva Neuroscience. He is a graduate of Miami University with a bachelors degree. Learn more:

CEO Marc Beer

Renovia Inc. will move forward with many new products for pelvic floor disorders. This is after it closed a recent Series B round financing with $32 million along with $10 million in venture debt.


The med-tech company that was co-founded by former Aegerion pharmaceuticals CEO marc beer is presently based in Boston. Renovia is creating an array of diagnostic and therapeutic products for the treatment of pelvic floor disorders such as urinary incontinence.


Researchers estimate that about 250 million women worldwide suffer urinary incontinence. Leva which is Renovia’s first product received approval from the FDA in April.


The series b funding round was led by New York-based perceptive advisors and Missouri based ascension ventures.


The Longwood Fund which was one of the early Renovia investors also joined the series b round. The funding is expected to be used in the testing of four more of Renovia’s diagnostic products including a new generation of the Leva device.


In a statement, Renovia’s CEO Marc beer said that they were happy to have the support from an elite group of healthcare investors who shared his company’s vision of better diagnosis, treatment, and improvement of the lives of millions of women affected by pelvic floor disorders.


He further said that by combining their innovative and proprietary sensor technologies with a digital health platform they would be giving clients crucial data that will inform treatment options and provide a better understanding of pelvic floor disorders.


Marc beer has over 20 years of experience in pharmaceuticals, biotechnology, and diagnostics.


In early 2000, Marc became founding CEO of Viacell, a biotechnology company that was dedicated tote collection and preservation of umbilical cord blood stem cells. Under marc’s prudent leadership the company quickly grew into a robust commercial


organization with hundreds of employees before being acquired by PerkinElmer in 2007.

Marc also served on the board of directors at Erytech Pharma while he was the CEO at Viacell. Before Viacell, he held various positions most notably as vice president of global marketing at Genzyme where he oversaw the launch of many products that were aimed at addressing rare diseases globally.


Marc is a former member of the mass life science board of the Commonwealth of Massachusetts and is the chairman of the compensation committee of GoodStart Genetics Inc. that was recently bought up by InVitae.


He is a member of the audit committee of the Minerva Neurosciences Inc. marc has a BS that he got from Miami University in Ohio. Learn more :